InterMune News

SAC Digs In as Deadline Nears for U.S. Insider Cases

Kyrgyzstan Decries Dismissal of U.S. Case Against Bakiyev

U.S. Case Ends Against Ex-Kyrgyz Leader Bakiyev’s Son

REUTERS SUMMIT-Drugmakers split as demands for open data mount

Big data is emerging as a big headache for the drug industry as regulators and advocates push for greater transparency on information from clinical trials, leaving companies split over how to respond. ...

After AbbVie's Humira: What Next?

INTERMUNE INC Files SEC form 10-Q, Quarterly Report

2 Biotechs To Avoid, 1 To Buy

2 Biotechs To Avoid, 1 To Buy

2 Biotechs To Avoid, 1 To Buy

Positive News in the Oncology Space Regarding Myeloma and Melanoma Drugs: Expert Analyst Boris Peaker Discusses Recent Successes for Biotechnology Companies

UPDATE 2-Europe's regulator digs in for drug data fight

The head of Europe's medicines regulator is digging in for a fight over data transparency after being stopped from releasing information on drugs from two U.S. companies by a court ruling. Defeat for the ...

CORRECTED-Court stops EU regulator releasing drug company data

Europe's medicines regulator has been stopped from releasing clinical trial data about drugs made by AbbVie and InterMune, following a court ruling favouring the two U.S. companies. The European Medicines ...

ITMN Crosses Above Key Moving Average Level

In trading on Monday, shares of InterMune Inc. crossed above their 200 day moving average of $9.16, changing hands as high as $9.38 per share.

Hedge funds are buying these stocks

InterMune Cuts Loss, Affirms View - Analyst Blog

InterMune's first-quarter loss per share of 66 cents was narrower than the Zacks Consensus Estimate of a loss of 76 cents.

InterMune's CEO Discusses Q1 2013 Results - Earnings Call Transcript

InterMune's CEO Discusses Q1 2013 Results - Earnings Call Transcript